Please try another search
For the fiscal year ended 31 December 2020, PandionTherapeutics Inc revenues increased from $967K to $8.8M.Net loss applicable to common stockholders increased 66% to$43M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Research anddevelopment increase of 67% to $24.8M (expense).
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 2.19 | 2.63 | 1.96 | 2 |
Gross Profit | ||||
Operating Income | -11.23 | -10.99 | -9.2 | -6.42 |
Net Income | -11.21 | -11.23 | -9.24 | -6.42 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 227.86 | 240.96 | 113.51 | 72.5 |
Total Liabilities | 13.13 | 16.12 | 23.4 | 15.16 |
Total Equity | 214.73 | 224.84 | 90.11 | 57.34 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -34.99 | -23.82 | -14.09 | -4.79 |
Cash From Investing Activities | -2.79 | -2 | -1.23 | -0.73 |
Cash From Financing Activities | 242.2 | 242.68 | 105.57 | 57.71 |
Net Change in Cash | 204.42 | 216.86 | 90.26 | 52.19 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review